Novo's Next Weight Loss Pill Isn't a GLP-1, And That's HUGE

What if the next big breakthrough in obesity medicine isn't a GLP-1 at all?

Novo Nordisk is developing an experimental oral weight-loss medication called LX9851, an ACSL5 inhibitor that targets an entirely different biological pathway than Ozempic, Wegovy, or Zepbound. Novo believes this once-daily pill could potentially deliver 10–15% weight loss without traditional dose titration.

But there's a catch. The drug is still in Phase 1 trials, and those weight-loss projections haven't been demonstrated in humans.

On this week's episode of On The Pen: The Weekly Dose, we're diving into Novo Nordisk's expanding obesity pipeline, the fascinating science behind the ACSL5 enzyme and the intestinal "ileal brake," and why this non-GLP-1 approach could eventually offer new options for patients who struggle with existing treatments.

We'll also examine the preclinical research, its potential alongside semaglutide, and why 2030 or later may be the earliest realistic timeline for this experimental therapy.

Could the future of obesity medicine be bigger than GLP-1s?

💬 Would you consider a weight-loss medication that doesn't directly activate GLP-1 receptors? Let me know in the comments!

🔗 All On The Pen resources, sponsors, and community links: https://linktr.ee/manonthemounjaro

🌐 Latest obesity medicine news: https://onthepen.com

🎙️ On The Pen Live: Monday, Wednesday, and Friday at 11 AM Central.

Subscribe for independent, patient-centered reporting on obesity medicine, GLP-1s, type 2 diabetes, clinical trials, and emerging metabolic therapies.

Disclaimer: LX9851 is investigational and not FDA-approved. Projected weight loss and development timelines are not established clinical outcomes. This content is for educational purposes and is not medical advice.